Nicotine Vaccination and Nicotinic Receptor Occupancy
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This is a molecular imaging research study designed to examine how much nicotine gets into
the brain before and after vaccination with NicVAX, a nicotine vaccine developed by Nabi
Biopharmaceuticals. NicVAX (Nicotine Conjugate Vaccine) is an investigational vaccine
designed as an aid to smoking cessation and long-term abstinence, as well as an aid to
prevent relapses of a treated smoker.
In this project we want to understand the degree to which NicVAX administration changes how
much nicotine enters the brain in smokers.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborators:
Nabi Biopharmaceuticals National Institute on Drug Abuse (NIDA)